Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.

Literature DB >> 8180022

Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.

E Tartour¹, T Dorval, V Mosseri, L Deneux, C Mathiot, H Brailly, F Montero, I Joyeux, P Pouillart, W H Fridman.

Abstract

Interleukin 6 and C-reactive protein (CRP) were determined prior to IL-2 therapy in sera from metastatic melanoma patients. Patients with elevated serum IL-6 (> 20 pg ml-1) and/or CRP (> 10 mg l-1) levels were associated with resistance to IL-2 therapy. A correlation between high serum IL-6 levels and a shorter median survival was also observed.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1994 PMID： 8180022 PMCID： PMC1968905 DOI： 10.1038/bjc.1994.175

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

17 in total

Review 1. Is the AIDS virus responsible for the disease?

Authors: G Mathé
Journal: Biomed Pharmacother Date: 1992 Impact factor: 6.529

Review 2. Cutaneous melanoma.

Authors: H K Koh
Journal: N Engl J Med Date: 1991-07-18 Impact factor: 91.245

3. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.

Authors: R O Dillman; C Church; R K Oldham; W H West; L Schwartzberg; R Birch
Journal: Cancer Date: 1993-04-01 Impact factor: 6.860

4. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells.

Authors: A Porgador; E Tzehoval; A Katz; E Vadai; M Revel; M Feldman; L Eisenbach
Journal: Cancer Res Date: 1992-07-01 Impact factor: 12.701

5. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression.

Authors: C Lu; M F Vickers; R S Kerbel
Journal: Proc Natl Acad Sci U S A Date: 1992-10-01 Impact factor: 11.205

6. Interleukin-6 production by human melanoma cell lines.

Authors: J D Lee; T M Sievers; M Skotzko; C F Chandler; D L Morton; W H McBride; J S Economou
Journal: Lymphokine Cytokine Res Date: 1992-06

7. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.

Authors: F M Marincola; D Venzon; D White; J T Rubin; M T Lotze; T B Simonis; J Balkissoon; S A Rosenberg; D R Parkinson
Journal: Cancer Res Date: 1992-12-01 Impact factor: 12.701

8. Pathologic concentrations of interleukin 6 inhibit T cell responses via induction of activation of TGF-beta.

Authors: D Zhou; A Munster; R A Winchurch
Journal: FASEB J Date: 1991-08 Impact factor: 5.191

9. Interleukin 2 therapy in cancer: identification of responders.

Authors: J Broom; S D Heys; P H Whiting; K G Park; A Strachan; I Rothnie; C R Franks; O Eremin
Journal: Br J Cancer Date: 1992-12 Impact factor: 7.640

10. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.

Authors: C Lu; R S Kerbel
Journal: J Cell Biol Date: 1993-03 Impact factor: 10.539

26 in total

Review 1. Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications.

Authors: R E Kast
Journal: Med Oncol Date: 2007 Impact factor: 3.064

2. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.

Authors: Renee C Prins; Brooks L Rademacher; Solange Mongoue-Tchokote; Joshi J Alumkal; Julie N Graff; Kristine M Eilers; Tomasz M Beer
Journal: Urol Oncol Date: 2010-03-06 Impact factor: 3.498

Review 3. Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management.

Authors: Nicole Kounalakis; James S Goydos
Journal: Curr Oncol Rep Date: 2005-09 Impact factor: 5.075

Review 4. Immunologic functions as prognostic indicators in melanoma.

Authors: Marna G Bouwhuis; Timo L M ten Hagen; Alexander M M Eggermont
Journal: Mol Oncol Date: 2011-02-03 Impact factor: 6.603

5. Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer.

Authors: Kotaro Hirashima; Masayuki Watanabe; Hironobu Shigaki; Yu Imamura; Satoshi Ida; Masaaki Iwatsuki; Takatsugu Ishimoto; Shiro Iwagami; Yoshifumi Baba; Hideo Baba
Journal: J Gastroenterol Date: 2013-07-03 Impact factor: 7.527

Review 6. The role of C-reactive protein as a prognostic indicator in advanced cancer.

Authors: Fade Aziz Mahmoud; Nilo I Rivera
Journal: Curr Oncol Rep Date: 2002-05 Impact factor: 5.075

7. Serum Levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in Patients with Oral Cavity Cancer.

Authors: Ewa Jablonska; Leszek Piotrowski; Zyta Grabowska
Journal: Pathol Oncol Res Date: 1997 Impact factor: 3.201

8. Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma.

Authors: Verena von Felbert; Francisco Córdoba; Jakob Weissenberger; Claudio Vallan; Masashi Kato; Izumi Nakashima; Lasse Roger Braathen; Joachim Weis
Journal: Am J Pathol Date: 2005-03 Impact factor: 4.307

9. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.

Authors: Matthew A Bill; James R Fuchs; Chenglong Li; Jennifer Yui; Courtney Bakan; Don M Benson; Eric B Schwartz; Dalia Abdelhamid; Jiayuh Lin; Dale G Hoyt; Stacey L Fossey; Gregory S Young; William E Carson; Pui-Kai Li; Gregory B Lesinski
Journal: Mol Cancer Date: 2010-06-25 Impact factor: 27.401

10. Melanoma biomarkers: Vox clamantis in deserto (Review).

Authors: Mays Al-Shaer; Divya Gollapudi; Chris Papageorgio
Journal: Oncol Lett Date: 2010-05-01 Impact factor: 2.967